On Jun. 1, 2020, OPKO Health announced the FDA had authorized OPKO to undertake a Phase 2 trial with RAYALDEEﾮ as a treatment for patients with mild-to-moderate COVID-19. The trial, entitled ﾓA Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of RAYALDEE (calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue),ﾔ was estimated to enroll 166 subjects, including many with stage 3 or 4 chronic kidney disease.